[go: up one dir, main page]

UY25436A1 - Combinaciones de estatina-inhibidor de mmp - Google Patents

Combinaciones de estatina-inhibidor de mmp

Info

Publication number
UY25436A1
UY25436A1 UY25436A UY25436A UY25436A1 UY 25436 A1 UY25436 A1 UY 25436A1 UY 25436 A UY25436 A UY 25436A UY 25436 A UY25436 A UY 25436A UY 25436 A1 UY25436 A1 UY 25436A1
Authority
UY
Uruguay
Prior art keywords
mmp inhibitor
statin
inhibitor combinations
combination
ldl
Prior art date
Application number
UY25436A
Other languages
English (en)
Inventor
Newton Roger Schofield Y David
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY25436A1 publication Critical patent/UY25436A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a una combinación de un compuesto de estatina,que se sabe que causa una reducción en los niveles plasmáticos de colesterol lipoproteínas de baja densidad (ldl),y un inhibidor de mmp,que reduce la ruptura de tejidos conectivos. La combinación es útil para tratar trastornos vasculares y prevenir la insuficiencia cardiaca.
UY25436A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp UY25436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
UY25436A1 true UY25436A1 (es) 2001-10-25

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25436A UY25436A1 (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp

Country Status (18)

Country Link
EP (1) EP1063991A1 (es)
JP (1) JP2002506818A (es)
KR (1) KR20010041916A (es)
AR (1) AR018113A1 (es)
AU (1) AU1591699A (es)
BR (1) BR9815745A (es)
CA (1) CA2309588A1 (es)
CO (1) CO5070670A1 (es)
GT (1) GT199900039A (es)
HN (1) HN1999000029A (es)
MY (1) MY140504A (es)
NZ (1) NZ505994A (es)
PA (1) PA8469001A1 (es)
PE (1) PE20000348A1 (es)
SV (1) SV1999000026A (es)
UY (1) UY25436A1 (es)
WO (1) WO1999047138A1 (es)
ZA (1) ZA992106B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
EP1827448A1 (en) 2004-12-15 2007-09-05 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors
SG166829A1 (en) * 2005-11-08 2010-12-29 Ranbaxy Lab Ltd Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636783T2 (de) * 1995-11-02 2007-10-18 Warner-Lambert Co. Llc Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration
CZ294063B6 (cs) * 1996-05-17 2004-09-15 Warner-Lambert Company Bifenylsulfonamid, jeho použití a farmaceutický prostředek s jeho obsahem
CA2263886A1 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
AU1591699A (en) 1999-10-11
GT199900039A (es) 2000-09-06
SV1999000026A (es) 2000-01-18
MY140504A (en) 2009-12-31
BR9815745A (pt) 2000-11-14
ZA992106B (en) 1999-09-30
KR20010041916A (ko) 2001-05-25
EP1063991A1 (en) 2001-01-03
HN1999000029A (es) 1999-09-29
WO1999047138A1 (en) 1999-09-23
CA2309588A1 (en) 1999-09-23
PE20000348A1 (es) 2000-05-22
PA8469001A1 (es) 2002-09-17
AR018113A1 (es) 2001-10-31
NZ505994A (en) 2003-10-31
CO5070670A1 (es) 2001-08-28
JP2002506818A (ja) 2002-03-05

Similar Documents

Publication Publication Date Title
AR032403A1 (es) Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
ES2188285T3 (es) Combinaciones de inhibidores del transporte de acidos biliares ileales y derivados de acido nicotinico para indicaciones cardiovasculares.
UY25268A1 (es) Inhibicion de la oxidacion de lipoproteinas
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
BR0315597A (pt) Processos de baixa dose para tratamento de distúrbios em que a atividade de tnf(alfa)é prejudicial
UY25322A1 (es) Compuestos de tiourea y benzamida,composiciones y metodos para tratar y prevenir enfermedades inflamatorias y aterosclerosis
UY25299A1 (es) Combinaciones de estatina-eter carboxialquílico
MXPA03006855A (es) Metodo para tratar insuficiencia cardiaca cronica y/o niveles elevados de colesterol, utilizando acido 3,5-diyodotiropropionico, y metodo para su preparacion.
EA199900837A1 (ru) Способ применения ингибиторов циклооксигеназы-2 для предупреждения сердечно-сосудистых расстройств
BR9911440A (pt) Composição para a prevenção e/ou tratamento de osteoporose e alterações devido à sìndrome de menopausa
ES2189529T3 (es) Combinaciones de inhiidores para el transporte de acidos biliares en el ileon y agentes complejantes para indicaciones cardiovasculares.
IL110943A (en) Compositions comprising an inhibitor of cholesterol synthesis for the treatment of skin disorders
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
PT942751E (pt) Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores
CL2004000366A1 (es) USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
BR9814885A (pt) Combinação de um inibidor da enzima de conversão da angiotensina e de um diurético para o tratamento das desordens microcirculatórias
UY25436A1 (es) Combinaciones de estatina-inhibidor de mmp
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
BR9713522A (pt) Método de uso de inibidores da cicloxigenase-2 como agentes antiangiogênicos.
TR200100901T2 (tr) Kateter-bazında revaskülarizasyonu önleme veya geciktirme yöntemi
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
BR9712307A (pt) Pirazolinonas para o tratamento de potência enfraquecida

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20110104